FindTrial
Sign In

TECHNETIUM (99MTC) COMPOUNDS

DRUG3 trials

Sponsors

Janssen - Cilag International

Conditions

Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)High risk recurrent prostate cancer previously treated with radical prostatectomyMetastatic Prostate Cancer

Phase 3

A Randomized, Controlled, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET, with an Observational Cohort
Active, not recruitingCTIS2023-505852-23-00
Janssen - Cilag InternationalHigh risk recurrent prostate cancer previously treated with radical prostatectomy
Start: 2020-11-12Target: 290Updated: 2025-07-21
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Active, not recruitingCTIS2023-506365-64-00
Janssen - Cilag InternationalDeleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Start: 2020-10-16Target: 211Updated: 2026-01-13
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer
Active, not recruitingCTIS2023-503254-12-00
Janssen - Cilag InternationalMetastatic Prostate Cancer
Start: 2019-03-06Target: 235Updated: 2025-12-09